Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10603957 | 0.88 | EGFR (0.53) | EGFRALDH1A1HPGDMAPTLMNA | |
| SCHEMBL10601747 | 0.88 | EGFR (0.65) | EGFRALDH1A1HPGDMAPTLMNA | |
| SCHEMBL9696260 | 0.87 | ESR1 (0.46) | ALDH1A1HPGDMAPTESR1ESR2 | |
| SCHEMBL9696028 | 0.84 | EGFR (0.42) | EGFRALDH1A1HPGDMAPTLMNA | |
| SCHEMBL7515538 | 0.83 | ALDH1A1 (0.47) | EGFRALDH1A1HPGDMAPTESR1 | |
| SCHEMBL21480766 | 0.82 | HPGD (0.57) | EGFRALDH1A1HPGDMAPTSRC | |
| SCHEMBL9696955 | 0.82 | MAPT (0.44) | EGFRALDH1A1HPGDMAPTESR1 | |
| SCHEMBL10604706 | 0.81 | EGFR (0.57) | EGFRALDH1A1HPGDMAPTLMNA | |
| SCHEMBL10793003 | 0.81 | EGFR (0.47) | EGFRALDH1A1HPGDMAPTLMNA | |
| SCHEMBL10603961 | 0.81 | EGFR (0.46) | EGFRHPGDLMNASRCCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061757-A1 | PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS | OLON SPA (IT) | 2021-03-04 | — | — | US | disclosed |
| WO-2019198023-A1 | PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS | OLON S.P.A. (IT) | 2019-10-17 | — | — | WO | disclosed |
| EP-0641770-B1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA CO (JP) | 1998-05-13 | — | — | EP | disclosed |
| US-5698692-A | INHIBIT BINDING BETWEEN PLATELET MEMBRANE GLYCOPROTEIN AND FIBRINOGEN | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-12-16 | — | — | US | disclosed |
| US-5594004-A | CARDIOVASCULAR DISORDERS AND ANTICOAGULANTS | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1997-01-14 | — | — | US | disclosed |
| EP-0641770-A1 | NOVEL COMPOUND WITH PLATELET AGGREGATION INHIBITOR ACTIVITY | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1995-03-08 | — | — | EP | disclosed |
| US-5144059-A | CATECHOLAMINE ESTERS | SIMES SOCIETA ITALIANA MEDICINALI E. SINTETICI S.A. (IT) | 1992-09-01 | — | — | US | disclosed |
| EP-0167204-B1 | METHOD FOR IMPROVING THE ABSORPTION AND EFFECTIVENESS OF A CATECHOLAMINE COMPOUND | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1989-09-27 | — | — | EP | disclosed |
| US-4673671-A | CONVERSION TO MONO O-PHOSPHATE ESTER | SIMES SOCIETA ITALIANA MEDICINALI E SINTETICI S.P.A. (IT) | 1987-06-16 | — | — | US | disclosed |
| EP-0167204-A1 | Method for improving the absorption and effectiveness of a catecholamine compound | SIMES S.p.A. Società Italiana Medicinali e Sintetici (IT) | 1986-01-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061757-A1 | PROCESS FOR THE SYNTHESIS OF OPTICALLY ACTIVE BETA-AMINO ALCOHOLS | ADH1C, ADH1A, ADH5 | EGFR 4141/4885ALDH1A1 35/4885HPGD 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.